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Abstract: 1 
Aims: 2 
We have developed a novel antimicrobial urinary catheter (AUC) impregnated with 3 
rifampicin, triclosan, and sparfloxacin and demonstrated that it has long-term (~84days) 4 
protection against bacterial colonisation in vitro. This study aimed to assess the safety and 5 
patient acceptability of this device in long-term catheter users. 6 
 7 
Methods: 8 
Adults who use longterm (>28days) indwelling urinary catheters with capacity to consent 9 
were invited to receive the AUC at their next catheter change. The primary outcome 10 
measure was adverse events (AE) attributable to antimicrobial impregnation of the catheter. 11 
Secondary outcome measures included severity of related AEs, patient acceptability, early 12 
removal of the trial catheter, and degree of microbial colonisation of trial catheters. Except 13 
for the last, outcomes were assessed by telephone interviews. Original and trial catheters 14 
were collected, and the lumens and balloons were separated and analysed for 15 
microbiological colonisation.  16 
 17 
Results: 18 
Thirty participants were recruited. 84 AEs were reported, and only one was rated as 19 
‘probably’ related to antimicrobial impregnation. The AE was mild and resolved within 48 20 
hours. 82.14% of participants rated the catheter as no different or better than their usual 21 
catheter. Two participants chose to remove the AUC early due to it feeling shorter. There 22 
were significantly fewer bacterial isolates attached to the balloons of trial catheters 23 
compared to the matched original catheters. 24 
 25 
Conclusions: 26 
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The AUC has an advantageous safety profile and was acceptable to the majority of 27 
participants. Information gained from this trial will support a larger randomised controlled 28 
study of efficacy.  29 
 30 
Keywords: urinary catheters, catheter-related urinary tract infections, anti-infective agents, 31 
safety, clinical trial 32 
 33 
Introduction: 34 
Catheter-associated urinary tract infections (CAUTI) are costly for health care 35 
systems as well as distressing for those who suffer from repeated infections and blockages. 36 
Long-term indwelling catheter users, who require catheterisation for over 28 days, are 37 
particularly at risk of CAUTI 1. Two antimicrobial catheters, a silver-alloy coated catheter and 38 
a nitrofurantoin-coated catheter have been commercially available, but a robust randomised 39 
controlled trial has demonstrated that neither significantly reduces CAUTI even in short-term 40 
catheter users. Also the patients who received the nitrofurantoin-coated catheter 41 
experienced greater discomfort than with the control catheter 2. Therefore, there is no 42 
commercially available anti-CAUTI technology for those who require catheterisation for over 43 
28 days.  44 
We have previously developed a silicone urinary catheters impregnated, not coated, 45 
with rifampicin, sparfloxacin, and triclosan and demonstrated seven to 12 weeks of 46 
protective activity against colonisation by major uropathogens, including multi-drug resistant 47 
strains3. The long-term duration of activity is conferred by the migration of the antimicrobials 48 
through the silicone to the intraluminal, extraluminal and balloon surfaces. Particularly, in 49 
light of the discomfort experienced with the nitrofurantoin-coated catheter, this study aims to 50 
understand primarily the tolerability of this novel antimicrobial urinary catheter (AUC) in the 51 
target patient population. Specifically, this was determined by the rate of adverse events 52 
(AEs) attributable to the antimicrobials or the antimicrobial impregnation process. Other 53 
secondary outcomes included patient acceptability, trial withdrawal, severity of AEs, time to 54 
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occurrence of AEs, microbial colonisation of the AUC. The trial was not intended to 55 
determine efficacy in reducing CAUTI, but instead to determine in human participants for the 56 
first time, the tolerability and acceptability of a novel antimicrobial-impregnated catheter for 57 
long-term use.  58 
 59 
 Materials and Methods: 60 
Patient and public involvement 61 
Lay members who were either longterm catheter users or carers were recruited to a 62 
research management committee to meet several times yearly to review the trial protocol, 63 
trial progress, and trial results. All travel expenses were covered and lay members received 64 
payment for attendance.  65 
 66 
Manufacture of trial devices 67 
Two-hundred and five all-silicone, two-way urinary catheters in sizes 12-20Ch 68 
standard and female lengths were impregnated according to a previously published method3-69 
5. Briefly, with any plastic ports and connectors removed, and catheters were immersed in a 70 
chloroform solution containing 0.2% w/v rifampicin (Sigma-Aldrich), 1.0% w/v triclosan 71 
(Irgacare MP, BASF) and 1.0% sparfloxacin (Sigma-Aldrich) for one hour. The catheters 72 
were removed and the chloroform was left to evaporate off under constant air flow for at 73 
least 12 hours. Surface residues were removed by rinsing in ethanol and the catheters left to 74 
dry. The catheters were packaged in individual plastic sleeves within Tyvek packaging with a 75 
clear front and opaque back. The catheters were sterilised by ethylene oxide and removal of 76 
ethylene oxide residuals was verified by gas chromatography by a Varian gas 77 
chromatograph using a 10 volt detector and 1 µL injection volume.  78 
Chloroform removal was verified by gas-chromatography-mass spectrometry in 79 
which catheter segments were immersed in acetone to extract the chloroform. Analysis was 80 
carried out using a JEOL AccuTOF GCX (Jeol Ltd.) mass spectrometer and an Agilent 81 
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7890B (Agilent Technologies Inc.) gas chromatograph. An extended ion current trace at 82.9 82 
mass to charge ratio (m/z) was used to detect chlorine isotopes. 83 
High-performance liquid chromatography (HPLC) was employed to verify antimicrobial 84 
contents of the manufactured trial catheters. Please see Supporting Information Method 1 for 85 
the full method of drug content analysis. Briefly, the antimicrobials were extracted in 86 
chloroform, resolubilised in methanol, and analysed by an Agilent 1100 HPLC machine with 87 
a variable wavelength UV detection (Agilent Technologies Inc). 88 
 89 
Participants and setting 90 
Adults (age 16 years or greater) who were catheterised with a long-term indwelling 91 
urinary catheter and who required another long-term indwelling urinary catheter were initially 92 
considered for inclusion. Please see Table 1 for the full inclusion and exclusion criteria.  93 
Participants were recruited from the community and hospital settings through letters of 94 
invitation and screening as participants came through Urology clinics 95 
  96 
Study design 97 
This single-centre, non-randomised trial with the aim of evaluating the safety of a CE-98 
marked medical device with modifications was carried out between November, 2016 and 99 
February, 2018. Eligible participants who provided informed consent were catheterised with 100 
the AUC (trial catheter) at their next scheduled catheter change date. They were 101 
catheterised with the AUC for their normal catheterisation length, which ranged from 28-84 102 
days. Participants were interviewed by telephone at 24, 48, and 72 hours post-103 
catheterisation and then once weekly for the rest of the trial duration. The original catheter 104 
and trial catheter were collected upon removal for laboratory analysis.  105 
The primary outcome measure was the rate of adverse events (AE) attributable to 106 
the antimicrobials or the impregnation process. All AEs were recorded in the case report and 107 
a score of severity and a score of relatedness to the AUC was given to each adverse event 108 
by the research nurse and adjudicated by the principal investigator. AEs were detected by 109 
Page 4 of 32
John Wiley & Sons
Neurourology & Urodynamics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
patient self-reporting during the telephone interview and followed up by a review of the 110 
patient’s notes. Relationship causality was classified as unrelated, unlikely, possible, 111 
probable or definite according to the algorithm given by the World Health Organisation6. 112 
Further classification grouped AEs as non-serious or serious. An AE was classified as 113 
serious (SAE) if it was fatal, life threatening, resulted in hospitalisation or prolonged 114 
hospitalisation or resulted in persistent or significant disability or incapacity.  115 
Secondary outcome measures included time to occurrence of adverse events, 116 
patient acceptability which was captured by the telephone interviews, whether the trial 117 
device was removed before the planned end date of the trial (trial withdrawal), and 118 
microorganism colonisati n of trial and original catheters.  119 
 120 
Laboratory analysis of removed catheters 121 
Catheters were analysed within 24 hours of removal. The balloon was separated 122 
from the lumen using a sterile scalpel and placed into a sterile Universal container and 123 
covered with phosphate buffered saline (PBS). The remaining ports on the catheter were 124 
also removed with a sterile scalpel and discarded. The remaining luminal tubing was filled 125 
with 1-2 mL of PBS, clamped using sterile, straight-jawed surgical clamps, and placed in a 126 
sterile container. The balloon and lumen components were sonicated for five minutes at 30 127 
kHz to detach the bacteria into the surrounding PBS. The luminal tubing ends were cleaned 128 
with an alcoholic pre-injection swab and the lumen sonicate was drained into a sterile Bijou 129 
bottle (Sterilin). The balloon and lumen sonicates were plated onto cysteine-lactose 130 
electrolyte-deficient medium (Oxoid), and incubated overnight at 37°C. If culture - positive, 131 
the colonies were quantified and general microbiological identification performed. If culture - 132 
negative the plates were incubated for a further 24 hours.  133 
 134 
Statistical analysis 135 
Data were analysed and graphs were prepared using GraphPad Prism 7.01 136 
(GraphPad Software Inc., LaJolla California, USA). 137 
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Results: 138 
Manufacture of trial devices 139 
Trial catheters were validated as being free of chloroform, and ethylene oxide 140 
sterilisation residuals were within the acceptable range. HPLC verified that the trial catheters 141 
were impregnated with 0.080% w/w (±0.013% w/w (IQR)) rifampicin, 1.084% w/w (± 0.138% 142 
w/w) triclosan, and 0.704% w/w (0.155% w/w) sparfloxacin.  143 
 144 
Participant Demographics 145 
 Thirty participants were recruited and were catheterised with the AUC. Please see 146 
Figure 1 for a STROBE fl w diagram of recruitment and participation. The majority of 147 
participants were male and except for one patient were catheterised urethrally (Table 2). The 148 
mean duration of catheterisation with the trial catheter was 56.03 days with a range of 1-84 149 
days. There were a total of 1681 days of participants catheterised with the AUC. 150 
 151 
Primary outcome: safety 152 
Eighty-four adverse events were reported by participants (0-11 AEs per participant). 153 
The majority (72.62%) of AEs were ‘unrelated’ or ‘unlikely’ to be related to the antimicrobial 154 
impregnation process. The AEs considered to be ‘possibly’ related to the AUC (26.19%) 155 
included blockage of the catheter, CAUTI episodes, and stinging after catheterisation as 156 
these are AEs associated with all urinary catheterisation (Table 3). The exception to this was 157 
one participant who experienced increased stinging following catheterisation that the 158 
participant had not experienced with previous catheters. This AE was classified as ‘probably’ 159 
related to antimicrobial impregnation of the catheters due to the noticeable difference 160 
between the AUC and the normal catheters. The stinging subsided within 48 hours and the 161 
participant then went on to consider the AUC no different from their normal catheter.  162 
Patient medical history was recorded at baseline and eight participants had a history 163 
of frequent CAUTIs. Four participants each experienced one CAUTI while using the AUC. 164 
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This provided a preliminary indication as to the potential efficacy of the AUC, but will need 165 
further systematic investigation.  166 
 167 
Secondary outcome: severity of AEs 168 
None of the AEs with any relationship to antimicrobial impregnation of the catheters 169 
was considered serious or severe as seen in Table 3. All SAEs were determined to be 170 
‘unrelated’ to antimicrobial impregnation of the urinary catheters. The participants were not 171 
withdrawn from the trial as a result of the SAEs and there were no restrictions on treatments 172 
received. 173 
 174 
Secondary outcome: time to occurrence of AEs 175 
There was no difference between time to AE in the AE causality relationship groups 176 
(p=0.5252. Log rank test). 177 
 178 
Secondary outcome: patient acceptability 179 
 82.14% of participants rated the AUC as no different or better than their previous 180 
catheters and 89.3% of participants reported the same amount of pain or less pain from the 181 
AUC at the last recorded interview (Table 4). 182 
A full thematic analysis of the free responses can be found as Supporting Information 183 
Table 1. At the last interview, three patients reported reduced infections, six commented on 184 
increased comfort, three wanted to keep the AUC for longer, and two wanted to have a 185 
second AUC. Impacts on mental health included getting better quality of sleep due to less 186 
need to empty the bladder via a valve and increased confidence in their catheter not 187 
becoming infected.  188 
 189 
Secondary outcome: trial withdrawal 190 
Nine of the 30 participants ended the trial earlier than expected. Seven were 191 
withdrawn because of catheter expulsion, a burst balloon, or balloon deflation. Bladder 192 
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stones were confirmed for the patient who had a burst balloon. One catheter was changed 193 
by a district nurse due to concerns that it may have been pulled out of position. The 194 
remaining two participants voluntarily ended the trial early, both due to what they felt was a 195 
shorter catheter length. However, both had received standard length catheters, which were 196 
400mm in length. No catheters were removed over safety concerns. 197 
 198 
Secondary outcome: colonisation of original and trial catheters 199 
Twenty-nine of the 30 original and 28 of the 30 AUCs were collected. The three lost 200 
catheters fell out in the community and could not be retrieved. The original catheters and 201 
AUCs were matched (n=27 pairs) and there were significantly fewer (p=0.0088, two-tailed t-202 
test) species of microorganisms attached to the AUC balloons compared to the matched 203 
control catheter. The pairs were well matched for the duration of catheterisation (p=0.8428, 204 
two-tailed t-test).  205 
The lumens of two trial catheters were culture - negative and no lumens of original 206 
catheters were culture - negative. One possible concern at the start of the study was that 207 
eradication of organisms sensitive to the activity of the AUC would allow replacement by 208 
other organisms. However, this was not seen in the catheter analyses. For example, E. 209 
faecalis is not sensitive to the activity of the AUC yet there was no overgrowth of E. faecalis 210 
in the AUCs. In fact, five fewer AUC balloons and two fewer lumens contained E. faecalis 211 
compared to the control catheters. In general, the presence of all groups of organisms was 212 
reduced in the AUCs, with the exception of Pseudmonas spp. in which there were two more 213 
AUC lumens colonised with Pseudomonas spp. compared to the control catheters. The main 214 
limitation of this analysis is that the numbers are small and future studies will be needed to 215 
monitor the colonising microorganism populations. It is important to emphasise that, though 216 
reduction in CAUTI was mentioned by three participants in the free comments (Supporting 217 
Information Table 1), this trial was not designed to quantify efficacy. 218 
 219 
Discussion: 220 
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Antimicrobial urinary catheters were produced and validated for use in this study, 221 
which is the first human trial of this device. 84 AEs in 30 participants across 1681 222 
catheterisation days were recorded, and of those only one was identified as being ‘probably’ 223 
related to antimicrobial impregnation. This event was worse stinging than usual at 224 
catheterisation and it resolved within 48 hours. The safety profile of the AUC appears 225 
favourable. Patient acceptability was positive with 82% of participants rating the AUC as ‘no 226 
different’ or better than their previous urinary catheters. Of the remaining 18% (5 227 
participants) responding “a bit worse”, two felt that their trial catheter was too short, despite it 228 
being of identical length to their standard catheter; one changed the type of drainage device 229 
and experienced disconnections; one experienced increased urinary urgency, and one 230 
experienced pain on passing urine using a catheter valve.  231 
Microbiological analysis of the participant’s original and trial catheters demonstrated 232 
a significant reduction of the number of species attached to the balloon of the AUCs. 233 
Importantly, the use of the AUC did not increase the prevalence of MDR organisms or 234 
increase the prevalence of microorganisms that are non-susceptible to the activity of the 235 
AUC. 236 
The CATHETER trial was a multi-centre randomised controlled trial of anti-septic 237 
(silver-alloy and nitrofurazone coated) catheters for short-term use. Patients receiving 238 
experimental catheters reported increased discomfort following catheterisation (silver 239 
catheter 28.7%, nitrofural catheter 38.9%) and this was a motivation for our obtaining data 240 
on safety and patient acceptability before undertaking larger studies. Our findings regarding 241 
comfort and acceptability compared very favourably with these. Haematuria and septicaemia 242 
were two recorded significant clinical events included in the CATHETER trial7. Haematuria 243 
and blockage of the catheter due to a blood clot were recorded during this trial, but there 244 
were alternative reasons for the presence of blood such as taking aspirin and the presence 245 
of an enlarged prostate which is a recognised cause of haematuria8. During adjudication of 246 
AE causality, as haematuria was not present without other predisposing factors and was no 247 
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worse than previous episodes, the episodes were determined as ‘possibly’ related as it is 248 
related to catheterisation but not necessarily catheterisation with the AUC. 249 
  The ESCALE trial, a trial of silver-alloy catheters in spinal cord injury patients, 250 
reported more AEs possibly related to catheterisation with the experimental catheters 251 
compared to standard catheters, including itching which was not reported in the control 252 
group9. Other AEs captured by the ESCALE trial included haematuria, rash, blockage, and 253 
suprapubic pain9. Rash related to catheterisation and suprapubic pain were not reported by 254 
patients in our AUC safety trial. Blockage was reported during this trial.  255 
Other unique AEs reported here included the sensation of needing to void, burning at 256 
the beginning and end of passing urine using a catheter valve, difficulty connecting the 257 
catheter bag to the catheter, and the catheter drainage system ‘pushing off’ the catheter 258 
connection. While these were mild events and mostly associated with the catheter drainage 259 
systems, they were still reported by participants as part of their catheter management. The 260 
base silicone urinary catheters that were impregnated with antimicrobials may have been 261 
from a different manufacturer than their normal catheter, which could have affected what the 262 
catheter user perceives as ‘normal’ for their catheter.  263 
Although the follow-up was short, any AEs relating to the composition of the catheter 264 
material are likely to have manifested in the time period studied. Further studies will confirm 265 
long-term tolerability as well as clinical efficacy and will benefit from a control arm for 266 
comparison. Other limitations include that this was an unblinded study and this may have 267 
introduced an element of bias of the participant’s in reporting. Although multi-centre trials 268 
provide a better generalisability of the results and therefore increased external validity, the 269 
participants represented many health conditions and were managed throughout several 270 
districts once catheterised with the trial catheter. Therefore, they were managed as standard 271 
according to their local policies and guidelines, which were not influenced by the clinical trial. 272 
In this trial participants were excluded if they not did have sensation in the urethra 273 
and/or bladder as they would be unable to self-report some symptoms and also for their 274 
safety. If the AUC were to cause irritation, allergy or discomfort both the participant and 275 
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research team would be unaware. This by extension excluded patients with spinal cord injury 276 
or cauda equina syndrome. Likewise, many patients with impaired cognitive capacity may 277 
require a urinary catheter but were not eligible to participate due to the possible inability to 278 
self-report new symptoms or adhere to the telephone interview schedule. These exclusion 279 
criteria were put in place to protect patients and to preserve the accuracy of the data 280 
collected. They will be included in a further randomised controlled trial of efficacy. 281 
 282 
Conclusions: 283 
The AUC has an advantageous safety profile and was an acceptable alternative 284 
catheter to the majority of trial participants. Information gained from this trial will support 285 
future regulatory applications for commercialisation and larger randomised controlled studies 286 
of efficacy of the AUC.  287 
 288 
 289 
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Table Legends:   323 
Table 1: Inclusion and exclusion criteria  324 
Table 2: Participant demographics of consented participants 325 
 326 
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Table 3: Description of adverse events (AEs), their relationship to antimicrobial impregnation 327 
of trial catheters and their severity 328 
 329 
Table 4: Replies from last recorded telephone interview of participants 330 
 331 
Figure Legends: 332 
Figure 1: STROBE flow diagram of participants involved throughout the trial pathway 333 
 334 
 335 
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Abstract: 1 
Aims: 2 
We have developed a novel antimicrobial urinary catheter (AUC) impregnated with 3 
rifampicin, triclosan, and sparfloxacin and demonstrated that it has long-term (~84days) 4 
protection against bacterial colonisation in vitro. This study aimed to assess the safety and 5 
patient acceptability of this device in long-term catheter users. 6 
 7 
Methods: 8 
Adults who use longterm (>28days) indwelling urinary catheters with capacity to consent 9 
were invited to receive the AUC at their next catheter change. The primary outcome 10 
measure was adverse events (AE) attributable to antimicrobial impregnation of the catheter. 11 
Secondary outcome measures included severity of related AEs, patient acceptability, early 12 
removal of the trial catheter, and degree of microbial colonisation of trial catheters. Except 13 
for the last, outcomes were assessed by telephone interviews. Original and trial catheters 14 
were collected, and the lumens and balloons were separated and analysed for 15 
microbiological colonisation.  16 
 17 
Results: 18 
Thirty participants were recruited. 84 AEs were reported, and only one was rated as 19 
‘probably’ related to antimicrobial impregnation. The AE was mild and resolved within 48 20 
hours. 82.14% of participants rated the catheter as no different or better than their usual 21 
catheter. Two participants chose to remove the AUC early due to it feeling shorter. There 22 
were significantly fewer bacterial isolates attached to the balloons of trial catheters 23 
compared to the matched original catheters. 24 
 25 
Conclusions: 26 
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The AUC has an advantageous safety profile and was acceptable to the majority of 27 
participants. Information gained from this trial will support a larger randomised controlled 28 
study of efficacy.  29 
 30 
Keywords: urinary catheters, catheter-related urinary tract infections, anti-infective agents, 31 
safety, clinical trial 32 
 33 
Introduction: 34 
Catheter-associated urinary tract infections (CAUTI) are costly for health care 35 
systems as well as distressing for those who suffer from repeated infections and blockages. 36 
Long-term indwelling catheter users, who require catheterisation for over 28 days, are 37 
particularly at risk of CAUTI 1. Two antimicrobial catheters, a silver-alloy coated catheter and 38 
a nitrofurantoin-coated catheter have been commercially available, but a robust randomised 39 
controlled trial has demonstrated that neither significantly reduces CAUTI even in short-term 40 
catheter users. Also the patients who received the nitrofurantoin-coated catheter 41 
experienced greater discomfort than with the control catheter 2. Therefore, there is no 42 
commercially available anti-CAUTI technology for those who require catheterisation for over 43 
28 days.  44 
We have previously developed a silicone urinary catheters impregnated, not coated, 45 
with rifampicin, sparfloxacin, and triclosan and demonstrated seven to 12 weeks of 46 
protective activity against colonisation by major uropathogens, including multi-drug resistant 47 
strains3. The long-term duration of activity is conferred by the migration of the antimicrobials 48 
through the silicone to the intraluminal, extraluminal and balloon surfaces. Particularly, in 49 
light of the discomfort experienced with the nitrofurantoin-coated catheter, this study aims to 50 
understand primarily the tolerability of this novel antimicrobial urinary catheter (AUC) in the 51 
target patient population. Specifically, this was determined by the rate of adverse events 52 
(AEs) attributable to the antimicrobials or the antimicrobial impregnation process. Other 53 
secondary outcomes included patient acceptability, trial withdrawal, severity of AEs, time to 54 
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occurrence of AEs, microbial colonisation of the AUC. The trial was not intended to 55 
determine efficacy in reducing CAUTI, but instead to determine in human participants for the 56 
first time, the tolerability and acceptability of a novel antimicrobial-impregnated catheter for 57 
long-term use.  58 
 59 
 Materials and Methods: 60 
Patient and public involvement 61 
Lay members who were either longterm catheter users or carers were recruited to a 62 
research management committee to meet several times yearly to review the trial protocol, 63 
trial progress, and trial results. All travel expenses were covered and lay members received 64 
payment for attendance.  65 
 66 
Manufacture of trial devices 67 
Two-hundred and five all-silicone, two-way urinary catheters in sizes 12-20Ch 68 
standard and female lengths were impregnated according to a previously published method3-69 
5. Briefly, with any plastic ports and connectors removed, and catheters were immersed in a 70 
chloroform solution containing 0.2% w/v rifampicin (Sigma-Aldrich), 1.0% w/v triclosan 71 
(Irgacare MP, BASF) and 1.0% sparfloxacin (Sigma-Aldrich) for one hour. The catheters 72 
were removed and the chloroform was left to evaporate off under constant air flow for at 73 
least 12 hours. Surface residues were removed by rinsing in ethanol and the catheters left to 74 
dry. The catheters were packaged in individual plastic sleeves within Tyvek packaging with a 75 
clear front and opaque back. The catheters were sterilised by ethylene oxide and removal of 76 
ethylene oxide residuals was verified by gas chromatography by a Varian gas 77 
chromatograph using a 10 volt detector and 1 µL injection volume.  78 
Chloroform removal was verified by gas-chromatography-mass spectrometry in 79 
which catheter segments were immersed in acetone to extract the chloroform. Analysis was 80 
carried out using a JEOL AccuTOF GCX (Jeol Ltd.) mass spectrometer and an Agilent 81 
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7890B (Agilent Technologies Inc.) gas chromatograph. An extended ion current trace at 82.9 82 
mass to charge ratio (m/z) was used to detect chlorine isotopes. 83 
High-performance liquid chromatography (HPLC) was employed to verify antimicrobial 84 
contents of the manufactured trial catheters. Please see Supporting Information Method 1 for 85 
the full method of drug content analysis. Briefly, the antimicrobials were extracted in 86 
chloroform, resolubilised in methanol, and analysed by an Agilent 1100 HPLC machine with 87 
a variable wavelength UV detection (Agilent Technologies Inc). 88 
 89 
Participants and setting 90 
Adults (age 16 years or greater) who were catheterised with a long-term indwelling 91 
urinary catheter and who required another long-term indwelling urinary catheter were initially 92 
considered for inclusion. Please see Table 1 for the full inclusion and exclusion criteria.  93 
Participants were recruited from the community and hospital settings through letters of 94 
invitation and screening as participants came through Urology clinics 95 
  96 
Study design 97 
This single-centre, non-randomised trial with the aim of evaluating the safety of a CE-98 
marked medical device with modifications was carried out between November, 2016 and 99 
February, 2018. Eligible participants who provided informed consent were catheterised with 100 
the AUC (trial catheter) at their next scheduled catheter change date. They were 101 
catheterised with the AUC for their normal catheterisation length, which ranged from 28-84 102 
days. Participants were interviewed by telephone at 24, 48, and 72 hours post-103 
catheterisation and then once weekly for the rest of the trial duration. The original catheter 104 
and trial catheter were collected upon removal for laboratory analysis.  105 
The primary outcome measure was the rate of adverse events (AE) attributable to 106 
the antimicrobials or the impregnation process. All AEs were recorded in the case report and 107 
a score of severity and a score of relatedness to the AUC was given to each adverse event 108 
by the research nurse and adjudicated by the principal investigator. AEs were detected by 109 
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patient self-reporting during the telephone interview and followed up by a review of the 110 
patient’s notes. Relationship causality was classified as unrelated, unlikely, possible, 111 
probable or definite according to the algorithm given by the World Health Organisation6. 112 
Further classification grouped AEs as non-serious or serious. An AE was classified as 113 
serious (SAE) if it was fatal, life threatening, resulted in hospitalisation or prolonged 114 
hospitalisation or resulted in persistent or significant disability or incapacity.  115 
Secondary outcome measures included time to occurrence of adverse events, 116 
patient acceptability which was captured by the telephone interviews, whether the trial 117 
device was removed before the planned end date of the trial (trial withdrawal), and 118 
microorganism colonisati n of trial and original catheters.  119 
 120 
Laboratory analysis of removed catheters 121 
Catheters were analysed within 24 hours of removal. The balloon was separated 122 
from the lumen using a sterile scalpel and placed into a sterile Universal container and 123 
covered with phosphate buffered saline (PBS). The remaining ports on the catheter were 124 
also removed with a sterile scalpel and discarded. The remaining luminal tubing was filled 125 
with 1-2 mL of PBS, clamped using sterile, straight-jawed surgical clamps, and placed in a 126 
sterile container. The balloon and lumen components were sonicated for five minutes at 30 127 
kHz to detach the bacteria into the surrounding PBS. The luminal tubing ends were cleaned 128 
with an alcoholic pre-injection swab and the lumen sonicate was drained into a sterile Bijou 129 
bottle (Sterilin). The balloon and lumen sonicates were plated onto cysteine-lactose 130 
electrolyte-deficient medium (Oxoid), and incubated overnight at 37°C. If culture - positive, 131 
the colonies were quantified and general microbiological identification performed. If culture - 132 
negative the plates were incubated for a further 24 hours.  133 
 134 
Statistical analysis 135 
Data were analysed and graphs were prepared using GraphPad Prism 7.01 136 
(GraphPad Software Inc., LaJolla California, USA). 137 
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Results: 138 
Manufacture of trial devices 139 
Trial catheters were validated as being free of chloroform, and ethylene oxide 140 
sterilisation residuals were within the acceptable range. HPLC verified that the trial catheters 141 
were impregnated with 0.080% w/w (±0.013% w/w (IQR)) rifampicin, 1.084% w/w (± 0.138% 142 
w/w) triclosan, and 0.704% w/w (0.155% w/w) sparfloxacin.  143 
 144 
Participant Demographics 145 
 Thirty participants were recruited and were catheterised with the AUC. Please see 146 
Figure 1 for a STROBE fl w diagram of recruitment and participation. The majority of 147 
participants were male and except for one patient were catheterised urethrally (Table 2). The 148 
mean duration of catheterisation with the trial catheter was 56.03 days with a range of 1-84 149 
days. There were a total of 1681 days of participants catheterised with the AUC. 150 
 151 
Primary outcome: safety 152 
Eighty-four adverse events were reported by participants (0-11 AEs per participant). 153 
The majority (72.62%) of AEs were ‘unrelated’ or ‘unlikely’ to be related to the antimicrobial 154 
impregnation process. The AEs considered to be ‘possibly’ related to the AUC (26.19%) 155 
included blockage of the catheter, CAUTI episodes, and stinging after catheterisation as 156 
these are AEs associated with all urinary catheterisation (Table 3). The exception to this was 157 
one participant who experienced increased stinging following catheterisation that the 158 
participant had not experienced with previous catheters. This AE was classified as ‘probably’ 159 
related to antimicrobial impregnation of the catheters due to the noticeable difference 160 
between the AUC and the normal catheters. The stinging subsided within 48 hours and the 161 
participant then went on to consider the AUC no different from their normal catheter.  162 
Patient medical history was recorded at baseline and eight participants had a 163 
history of frequent CAUTIs. Four participants each experienced one CAUTI while 164 
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using the AUC. This provided a preliminary indication as to the potential efficacy of 165 
the AUC, but will need further systematic investigation.  166 
 167 
Secondary outcome: severity of AEs 168 
None of the AEs with any relationship to antimicrobial impregnation of the catheters 169 
was considered serious or severe as seen in Table 3. All SAEs were determined to be 170 
‘unrelated’ to antimicrobial impregnation of the urinary catheters. The participants were not 171 
withdrawn from the trial as a result of the SAEs and there were no restrictions on treatments 172 
received. 173 
 174 
Secondary outcome: time to occurrence of AEs 175 
There was no difference between time to AE in the AE causality relationship groups 176 
(p=0.5252. Log rank test). 177 
 178 
Secondary outcome: patient acceptability 179 
 82.14% of participants rated the AUC as no different or better than their previous 180 
catheters and 89.3% of participants reported the same amount of pain or less pain from the 181 
AUC at the last recorded interview (Table 4). 182 
A full thematic analysis of the free responses can be found as Supporting Information 183 
Table 1. At the last interview, three patients reported reduced infections, six commented on 184 
increased comfort, three wanted to keep the AUC for longer, and two wanted to have a 185 
second AUC. Impacts on mental health included getting better quality of sleep due to less 186 
need to empty the bladder via a valve and increased confidence in their catheter not 187 
becoming infected.  188 
 189 
Secondary outcome: trial withdrawal 190 
Nine of the 30 participants ended the trial earlier than expected. Seven were 191 
withdrawn because of catheter expulsion, a burst balloon, or balloon deflation. Bladder 192 
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stones were confirmed for the patient who had a burst balloon. One catheter was changed 193 
by a district nurse due to concerns that it may have been pulled out of position. The 194 
remaining two participants voluntarily ended the trial early, both due to what they felt was a 195 
shorter catheter length. However, both had received standard length catheters, which were 196 
400mm in length. No catheters were removed over safety concerns. 197 
 198 
Secondary outcome: colonisation of original and trial catheters 199 
Twenty-nine of the 30 original and 28 of the 30 AUCs were collected. The three lost 200 
catheters fell out in the community and could not be retrieved. The original catheters and 201 
AUCs were matched (n=27 pairs) and there were significantly fewer (p=0.0088, two-tailed t-202 
test) species of microorganisms attached to the AUC balloons compared to the matched 203 
control catheter. The pairs were well matched for the duration of catheterisation (p=0.8428, 204 
two-tailed t-test).  205 
The lumens of two trial catheters were culture - negative and no lumens of original 206 
catheters were culture - negative. One possible concern at the start of the study was that 207 
eradication of organisms sensitive to the activity of the AUC would allow replacement by 208 
other organisms. However, this was not seen in the catheter analyses. For example, E. 209 
faecalis is not sensitive to the activity of the AUC yet there was no overgrowth of E. faecalis 210 
in the AUCs. In fact, five fewer AUC balloons and two fewer lumens contained E. faecalis 211 
compared to the control catheters. In general, the presence of all groups of organisms was 212 
reduced in the AUCs, with the exception of Pseudmonas spp. in which there were two more 213 
AUC lumens colonised with Pseudomonas spp. compared to the control catheters. The main 214 
limitation of this analysis is that the numbers are small and future studies will be needed to 215 
monitor the colonising microorganism populations. It is important to emphasise that, though 216 
reduction in CAUTI was mentioned by three participants in the free comments (Supporting 217 
Information Table 1), this trial was not designed to quantify efficacy. 218 
 219 
Discussion: 220 
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Antimicrobial urinary catheters were produced and validated for use in this study, 221 
which is the first human trial of this device. 84 AEs in 30 participants across 1681 222 
catheterisation days were recorded, and of those only one was identified as being ‘probably’ 223 
related to antimicrobial impregnation. This event was worse stinging than usual at 224 
catheterisation and it resolved within 48 hours. The safety profile of the AUC appears 225 
favourable. Patient acceptability was positive with 82% of participants rating the AUC as ‘no 226 
different’ or better than their previous urinary catheters. Of the remaining 18% (5 227 
participants) responding “a bit worse”, two felt that their trial catheter was too short, despite it 228 
being of identical length to their standard catheter; one changed the type of drainage device 229 
and experienced disconnections; one experienced increased urinary urgency, and one 230 
experienced pain on passing urine using a catheter valve.  231 
Microbiological analysis of the participant’s original and trial catheters demonstrated 232 
a significant reduction of the number of species attached to the balloon of the AUCs. 233 
Importantly, the use of the AUC did not increase the prevalence of MDR organisms or 234 
increase the prevalence of microorganisms that are non-susceptible to the activity of the 235 
AUC. 236 
The CATHETER trial was a multi-centre randomised controlled trial of anti-septic 237 
(silver-alloy and nitrofurazone coated) catheters for short-term use. Patients receiving 238 
experimental catheters reported increased discomfort following catheterisation (silver 239 
catheter 28.7%, nitrofural catheter 38.9%) and this was a motivation for our obtaining data 240 
on safety and patient acceptability before undertaking larger studies. Our findings regarding 241 
comfort and acceptability compared very favourably with these. Haematuria and septicaemia 242 
were two recorded significant clinical events included in the CATHETER trial7. Haematuria 243 
and blockage of the catheter due to a blood clot were recorded during this trial, but there 244 
were alternative reasons for the presence of blood such as taking aspirin and the presence 245 
of an enlarged prostate which is a recognised cause of haematuria8. During adjudication of 246 
AE causality, as haematuria was not present without other predisposing factors and was no 247 
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worse than previous episodes, the episodes were determined as ‘possibly’ related as it is 248 
related to catheterisation but not necessarily catheterisation with the AUC. 249 
  The ESCALE trial, a trial of silver-alloy catheters in spinal cord injury patients, 250 
reported more AEs possibly related to catheterisation with the experimental catheters 251 
compared to standard catheters, including itching which was not reported in the control 252 
group9. Other AEs captured by the ESCALE trial included haematuria, rash, blockage, and 253 
suprapubic pain9. Rash related to catheterisation and suprapubic pain were not reported by 254 
patients in our AUC safety trial. Blockage was reported during this trial.  255 
Other unique AEs reported here included the sensation of needing to void, burning at 256 
the beginning and end of passing urine using a catheter valve, difficulty connecting the 257 
catheter bag to the catheter, and the catheter drainage system ‘pushing off’ the catheter 258 
connection. While these were mild events and mostly associated with the catheter drainage 259 
systems, they were still reported by participants as part of their catheter management. The 260 
base silicone urinary catheters that were impregnated with antimicrobials may have been 261 
from a different manufacturer than their normal catheter, which could have affected what the 262 
catheter user perceives as ‘normal’ for their catheter.  263 
Although the follow-up was short, any AEs relating to the composition of the catheter 264 
material are likely to have manifested in the time period studied. Further studies will confirm 265 
long-term tolerability as well as clinical efficacy and will benefit from a control arm for 266 
comparison. Other limitations include that this was an unblinded study and this may have 267 
introduced an element of bias of the participant’s in reporting. Although multi-centre trials 268 
provide a better generalisability of the results and therefore increased external validity, the 269 
participants represented many health conditions and were managed throughout several 270 
districts once catheterised with the trial catheter. Therefore, they were managed as standard 271 
according to their local policies and guidelines, which were not influenced by the clinical trial. 272 
In this trial participants were excluded if they not did have sensation in the urethra 273 
and/or bladder as they would be unable to self-report some symptoms and also for their 274 
safety. If the AUC were to cause irritation, allergy or discomfort both the participant and 275 
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research team would be unaware. This by extension excluded patients with spinal cord injury 276 
or cauda equina syndrome. Likewise, many patients with impaired cognitive capacity may 277 
require a urinary catheter but were not eligible to participate due to the possible inability to 278 
self-report new symptoms or adhere to the telephone interview schedule. These exclusion 279 
criteria were put in place to protect patients and to preserve the accuracy of the data 280 
collected. They will be included in a further randomised controlled trial of efficacy. 281 
 282 
Conclusions: 283 
The AUC has an advantageous safety profile and was an acceptable alternative 284 
catheter to the majority of trial participants. Information gained from this trial will support 285 
future regulatory applications for commercialisation and larger randomised controlled studies 286 
of efficacy of the AUC.  287 
 288 
 289 
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Table Legends:   323 
Table 1: Inclusion and exclusion criteria  324 
Table 2: Participant demographics of consented participants 325 
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Table 3: Description of adverse events (AEs), their relationship to antimicrobial impregnation 327 
of trial catheters and their severity 328 
 329 
Table 4: Replies from last recorded telephone interview of participants 330 
 331 
Figure Legends: 332 
Figure 1: STROBE flow diagram of participants involved throughout the trial pathway 333 
 334 
 335 
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Reviewer 2: 
 
    3.     Why is the data from the normal catheters included in table 3? It would be nice to 
compare the two for all these outcomes. 
     
    Answer: Table 3 presents the adverse events recorded during catheterisation with the 
antimicrobial-impregnated urinary catheter and not the normal catheters. 
     
    Reply: This is a rather unsatisfying answer. You have evaluated normal catheters for bacterial 
evaluation and compared in large sections the antimicrobial catheters with normal catheters 
(culturing etc.) and mirror tolerability between the two (being either patient reported or else). The 
primary aim of your study is safety and part of this is tolerability of this new catheter, but why is this 
then not systematically evaluated / reported by comparing them with the normal catheter, while 
you did do it for many other aspects of your study? Evaluation of the applicability of the new 
antimicrobial catheter will be based on an established balance between efficacy (reduced CAUTI and 
tolerability compared to normal catheters. Because there is no evaluation of efficacy of the catheter 
(amount of CAUTI'S) in this study, there should therefore have been be a systematic focus on 
tolerability by comparing table 3 parameters with a normal catheter in my opinion.        
     
Reply to reviewer: Please find additional information in the manuscript (Lines 
164-167) regarding efficacy data from baseline and with catheterisation with 
the antimicrobial catheter.  
 
A comparison of tolerability between normal and antimicrobial catheters by 
patient self-reporting was carried out at each telephone interview. This 
information was summarised in Table 4. 
 
 According to the trial protocol, eligible participants were consented and after 
consent their normal catheter was removed and collected for analysis. The 
participant was catheterised with the antimicrobial catheter and followed up 
according to the telephone interview schedule. Therefore, normal catheters 
were not followed up in the same systematic manner as the aim of this study 
was to understand the safety profile of the AUC ‘Specifically, this was determined 
by the rate of adverse events (AEs) attributable to the antimicrobials or the antimicrobial 
impregnation process’ (lines 53-54). As we know which AEs are attributable to a 
normal urinary catheter, we determined that there was only one AE that was 
possibly related to antimicrobial impregnation, which was heightened stinging 
immediately following catheterisation. Comparison of patient responses when 
using the AUC with their experience of the previous, plain catheter (Table 4) 
showed that 42.31% found it an improvement and 39.29% found it no 
different. In this way, we consider that we have done as the Reviewer 
requested, in that we have a comparison of the AUC with the previous plain 
catheter. To express this in terms of individual responses for each patient 
would consume a large amount of space but would not, in our view, add useful 
data. 
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A safety and patient acceptability pilot study of a novel antimicrobial urinary catheter for 
long-term use 
 
Supporting Information 
Method 1: 
Three 1.0 cm segments from five catheters were individually immersed in 2.0 mL 
chloroform to extract the drugs. This was repeated twice more and the extracts in chloroform 
were pooled together and the chloroform was removed under constant air flow. The extracts 
were re-solubilised in 100% methanol (HPLC grade, Fisher Scientific). Analysis was carried 
out by an Agilent 1100 HPLC machine with a variable wavelength UV detector (Agilent 
Technologies Inc.) connected to a Chemstation operating system. Chromatographic 
separations were performed using an Eclipse XDB-C8 (5µm, i.d. 4.6mm x 150 mm) column 
(Agilent Technologies). The mobile phase was a mixture of 10% acetonitrile (HPLC grade, 
Fisher Scientific) and aqueous sodium dihydrogen phosphate (Sigma-Aldrich) adjusted to 
15mM and pH 2.5. The organic phase was 100% methanol. A gradient method was 
employed and maintained a flow rate of 1.0 mL/min and an injection volume of 5.0 µL with 
each run lasting eight minutes. The starting solvent concentration was 90% aqueous phase, 
10% methanol increasing to 90% methanol after one minute and decreasing to 10% 
methanol at four minutes. Eluted drugs were first read at a wavelength of 254 nm to detect 
rifampicin and sparfloxacin, and then 279 nm to detect triclosan. The retention times were 
approximately 3.0, 3.6, and 4.5 minutes for sparfloxacin, rifampicin, and triclosan, 
respectively.  
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Table 1: Thematic analysis of free text responses to the question ‘How would you rate this 
catheter compared to your usual?’ for the first and last telephone interviews along with the 
number of free responses fitting into each sub-theme 
First Interview Number Last Interview Number 
Main Themes Sub-Themes Main Themes Sub-Themes 
No noticeable 
difference to 
previous 
catheters 
Too soon to 
make a 
judgement 
6 No noticeable 
difference to 
previous catheters 
Cannot tell a 
difference 
9 
Cannot tell a 
difference 
8 Catheter 
maintenance 
Infection reduction 3 
Catheter 
maintenance 
Urine flow 4 Leakage and 
bypassing 
2 
Leakage and 
bypassing 
3 Catheter valve issues 2 
Catheter 
comfort 
Stinging and 
soreness 
6 Catheter comfort Improved comfort 6 
Improved 
sensation 
3 Discomfort 3 
Mental Health Beneficial 
impact on 
mental health  
2 Catheter material 1 
Mental Health Beneficial impact on 
mental health  
2 
Participant 
satisfaction 
Desire to keep the 
AUC 
3 
Desire to have a 
second AUC 
2 
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Table 1: 
Inclusion Criteria 
Age: 16 years old or greater 
Currently fitted with a urinary catheter for at least 28 days and 
will require another urinary catheter for 28 days or greater 
Able to understand written English and speak English fluently 
Able to verbally respond and to speak on the telephone 
 
Exclusion Criteria 
Pregnant or likely to become pregnant 
Adults lacking the ability to consent for themselves 
Allergy to: 
- Rifampicin 
- Sparfloxacin or any other fluoroquinolone antibiotics 
- Triclosan 
- Silicone  
History of uncontrolled/unmanageable autonomic dysreflexia 
Significantly impaired sensation of the bladder and/or urethra 
 
 
Table 2: 
Trial Participants (n=30) 
Age (years)  
 Mean  71.4 
 Range 43 - 92 
Gender  
 Female 4/30 (13.3%) 
Male 26/30 (86.7%) 
Catheterisation Route  
 Urethral 29/30 (96.7%) 
Suprapubic 1/30 (3.3%) 
Reason for catheterisation  
 Acute retention 12/30 (40.0%) 
Chronic retention 11/30 (36.7%) 
Chronic retention with 
incontinence 
2/30 (6.6%) 
Incontinence 2/30 (6.6%) 
Neurogenic bladder 1/30 (3.3%) 
Urethral stricture 1/30 (3.3%) 
Immobility 1/30 (3.3%) 
Catheter lumen size  
 12 Ch 7/30 (23.3%) 
14 Ch 18/30 (60.0%) 
16 Ch 5/30 (16.7%) 
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Table 3: 
AE relationship to antimicrobial 
impregnation of the trial catheters 
Number of AEs 
Mild Moderate Severe Total 
AE ‘Unrelated’  37 14 5 
56 
(66.67%) 
AE ‘Unlikely’ 4 1 0 5 (5.95%) 
   Pelvic infection 1   1 
   Dizzy after catheterisation 1   1 
   Catheter fell out spontaneously 1   1 
   Dizziness/generally unwell  1  1 
   Catheter displaced due to bag being full  
   and falling off catheter strap 
1   1 
AE ‘Possibly’ 19 3 0 
22 
(26.19%) 
   CAUTI 2 2  4 
   Blockage 4 1  5 
   Burning at the beginning and end of  
   passing urine via the flip flow valve 
2   2 
   Early catheter change due to perceived 
shorter length 
2   2 
   Catheter expulsion 1   1 
   Bypassing catheter 1   1 
   Sensation of needing to void 1   1 
   Catheter bag/valve pushing off 
connection 
1   1 
   Haematuria 1   1 
   Stinging  1   1 
   Testicular ache 1   1 
   Difficulty connecting the catheter bag to  
   catheter 
1   1 
   Small sore on foreskin 1   1 
AE ‘Probably’  1 0 0 1 (1.19%) 
  Heightened stinging following 
catheterisation 
1   1 
 
Table 4: 
Telephone interview question Participant Responses 
Response Percentage of 
responses 
‘How would you rate this catheter 
compared to your usual catheter?’ 
Much better 35.17% 
A bit better 7.14% 
No different 39.29% 
A bit worse 17.86% 
Much worse 0.0% 
‘Have you had any pain from the 
catheter’ 
Less than usual 32.14% 
About the same 57.14% 
More than usual 10.71% 
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